1-4 of 4
Nancy Contel
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Long-Term Efficacy and Safety Results From a Phase II Study of Ruxolitinib in Patients with Polycythemia Vera

Srdan Verstovsek, MD, PhD, Francesco Passamonti, MD, Alessandro Rambaldi, MD, Giovanni Barosi, MD, Peter J. Rosen, MD, Shui He, PhD, Nancy Contel, DVM, Bijoyesh Mookerjee, MD, FACP, Elisa Rumi, MD, Elisabetta Gattoni, MD, Lisa Pieri, MD, Mario Cazzola, MD, Hagop M. Kantarjian, MD, Tiziano Barbui, MD, Alessandro M. Vannucchi, MD
Journal: Blood
Blood (2012) 120 (21): 804.
https://doi.org/10.1182/blood.V120.21.804.804
Published: 2012
Journal Articles

Treatment with Ruxolitinib (INCB018424) Induced Changes of Microrna Expression in Granulocytes of Patients with Polycythemia Vera and Essential Thrombocythemia,

Paola Guglielmelli, MD, PhD, Lisa Pieri, MD, Enrico Tagliarico, MD, Roberta Zini, BiSci, Ruggiero Norfo, PhD, Alberto Bosi, Kris Vaddi, PhD, DVM, Timothy Burn, PhD, Nancy Contel, Srdan Verstovsek, MD, PhD, Rossella Manfredini, BiSci, PhD, Alessandro M. Vannucchi, MD
Journal: Blood
Blood (2011) 118 (21): 3852.
https://doi.org/10.1182/blood.V118.21.3852.3852
Published: 2011
Journal Articles

Durable Responses with the JAK1/ JAK2 Inhibitor, INCB018424, In Patients with Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Refractory or Intolerant to Hydroxyurea (HU)

Srdan Verstovsek, MD, PhD, Francesco Passamonti, Alessandro Rambaldi, MD, Giovanni Barosi, MD, Peter J. Rosen, MD, Richard Levy, Edward Bradley, William Garrett, Kris Vaddi, Nancy Contel, Victor Sandor, Reid Michael Huber, PhD, Lee P. Schacter, MD, PhD, Elisa Rumi, Elisabetta Gattoni, Elisabetta Antonioli, Lisa Pieri, MD, Mario Cazzola, MD, Hagop Kantarjian, MD, Tiziano Barbui, MD, Alessandro M. Vannucchi, MD
Journal: Blood
Blood (2010) 116 (21): 313.
https://doi.org/10.1182/blood.V116.21.313.313
Published: 2010
Journal Articles

A Phase 2 Study of INCB018424, An Oral, Selective JAK1/JAK2 Inhibitor, in Patients with Advanced Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Refractory to Hydroxyurea.

Srdan Verstovsek, MD, PhD, Francesco Passamonti, Alessandro Rambaldi, MD, Giovanni Barosi, MD, Peter Rosen, MD, Richard Levy, MD, Edward C Bradley, MD, Lee Schacter, William M Garrett, MBA, Kris Vaddi, Ph.D., Nancy Contel, Elisa Rumi, Elisabetta Gattoni, MD, Mario Cazzola, Hagop Kantarjian, Tiziano Barbui, Alessandro Vannucchi
Journal: Blood
Blood (2009) 114 (22): 311.
https://doi.org/10.1182/blood.V114.22.311.311
Published: 2009